This press release is a routine clinical data presentation with no immediate financial or regulatory catalyst for Teva. Traders should monitor for any future regulatory actions or label expansions related to TD treatments, but no near-term stock-moving event is indicated.
TEVA drugs
TEVA drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 18 $34.03entry
- T+1 · 6mo ago +0.13%α +0.78% · $34.07
- T+5 · 6mo ago +1.70%α +0.09% · $34.61
- T+20 · 5mo ago −0.99%α −3.18% · $33.69
- T+60 · 3mo ago +7.67%α +3.09% · $36.64
Price Chart
How similar events traded
Executive Summary
Teva presented new IMPACT-TD Registry data at the 2026 APA Annual Meeting, revealing that 85% of young adults (18-29) with mood disorders and tardive dyskinesia experience moderate-to-severe impact, yet only 23% received a formal diagnosis. The data highlights a significant diagnostic gap and underscores Teva's commitment to TD research, but the press release contains no financial figures, no regulatory decision, and no change to Teva's commercial outlook.
Key Facts
- New IMPACT-TD Registry data presented at APA 2026 shows 85% of young adults (18-29) with mood disorders and TD experience moderate-to-severe impact.
- Only 23% of young adults (18-29) with TD received a formal diagnosis, revealing a diagnostic gap.
- Average delay in TD diagnosis is more than 3.5 years after involuntary movements are first recognized.
- The IMPACT-TD Registry is a 3-year, prospective, Phase 4 study with 611 participants.
- No financial data, revenue figures, or changes to Teva's product pipeline were disclosed in the press release.
Financial Impact
No financial impact disclosed; the press release is a clinical data update with no revenue or earnings implications.
Risk Factors
- No new commercial or regulatory catalyst; the data does not change Teva's near-term revenue or earnings outlook.
- Diagnostic gap findings may not translate into increased prescribing or market share for Teva's TD treatments.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3296535 |
Track record
61 reports on TEVA
6 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +33.06% at T+60 after the Jul 20, 2026 report. 15 of 17 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $43.16 Now $42.57 −1.37% settles Feb 12
- Nov 12, 20264d ago 3 Neutral 2/10 Entry $44.50 Now $42.57 −4.34% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $44.50 Now $42.57 −4.34% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $43.65 Now $42.57 −2.47% settles Feb 10
- Nov 10, 20266d ago 144 Neutral 3/10 Entry $43.24 Now $42.57 −1.55% settles Feb 9
- Nov 10, 20266d ago SC 13G/A Neutral 3/10 Entry $42.40 Now $42.57 +0.40% settles Feb 8
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $42.40 Now $42.57 +0.40% settles Feb 8
- Nov 6, 202610d ago Insider Cluster Neutral 3/10 Entry $42.97 Now $42.57 −0.93% settles Feb 5
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $42.97 Now $42.57 −0.93% settles Feb 5
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $42.61 Now $42.57 −0.09% settles Feb 4
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers